Pooled patient level data are better suited than study level data to investigate the link between dipeptidyl peptidase-4 inhibitors and the risk of heart failure in type 2 diabetes

BMJ. 2016 May 24:353:i2920. doi: 10.1136/bmj.i2920.

Authors

Tejas Patel¹, Bereket Tesfaldet¹, Charu Gandotra²; Meta-AnalyTical Interagency Group (MATIG) (Keith Burkhart, MD; Henry Chang, MD; Jue Chen, MS, PhD; Sean Coady, MS; Lawton Cooper, MD; Gyorgy Csako, MD; Michelle Fennessy, RN, PhD; Jerome Fleg, MD; Ahmed Hasan, MD, PhD, FACC; Ruth Kirby, BS, RN; Eileen Navarro Almario, MD, MS, FACP; Frank Pucino, PharmD, MPH; Subha Raman, MD; Yves Rosenberg, MD, MPH; George Sopko, MD; Helena Sviglin, MPH; Robert Wesley, PhD

Affiliations

¹ Food and Drug Administration, 10993 New Hampshire Avenue, Silver Spring, MD 20993, USA.
² Division of Cardiovascular Medicine, Department of Internal Medicine, Howard University Hospital, Washington, DC, USA.

PMID: 27220716
DOI: 10.1136/bmj.i2920

No abstract available

Publication types

Letter

MeSH terms

Data Interpretation, Statistical*
Diabetes Mellitus, Type 2 / drug therapy*
Dipeptidyl-Peptidase IV Inhibitors / adverse effects*
Heart Failure / chemically induced*
Humans
Hypoglycemic Agents / adverse effects*
Meta-Analysis as Topic
Review Literature as Topic
Risk Assessment / methods*

Substances

Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents